Literature DB >> 27354275

Circulating vascular endothelial growth factor and the risk of cardiovascular events.

Bernhard M Kaess1,2, Sarah R Preis1,3, Alexa Beiser1,3,4, Douglas B Sawyer5, Tai C Chen6, Sudha Seshadri1,4, Ramachandran S Vasan1,7.   

Abstract

OBJECTIVE: To investigate the relation of circulating concentrations of vascular endothelial growth factor (VEGF) for the risk of developing cardiovascular disease (CVD) in a large community-based sample.
METHODS: We prospectively assessed the relation of circulating VEGF concentrations with the incidence of CVD among 3041 Framingham Heart Study participants (mean age 63.4±11.1 years, 59% women). Multivariable Cox proportional hazards models were estimated adjusting for standard risk factors to VEGF quartiles to incident CVD. Restricted cubic splines were used to examine the linearity of the association.
RESULTS: After a mean follow-up of 8.8 (±2.8) years, 527 individuals experienced a first CVD event. Compared with participants in the first VEGF quartile, individuals in the second VEGF quartile had a 34% increased risk for future CVD (HR 1.34, 95% CI 1.03 to 1.74; p value=0.03) and individuals in third quartile had a 59% higher risk (HR 1.59; 95% CI 1.23 to 2.05, p value=0.0003). Individuals in the highest VEGF quartile had a similar cardiovascular risk as compared with those in the lowest VEGF quartile (HR 1.18, 95% CI 0.91 to 1.53, p value=0.21). Evaluation of restricted cubic splines confirmed the nonlinear, inverted U-shaped relation of serum VEGF and CVD events (p<0.0001 for model fit, p=0.006 for non-linearity).
CONCLUSIONS: Circulating VEGF concentrations exhibit a complex non-linear (inverted U-shaped) relation with the risk of developing CVD events, with the lowest risk experienced at the lower and upper end of the distribution. The underlying pathophysiological mechanisms remain to be elucidated. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27354275     DOI: 10.1136/heartjnl-2015-309155

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  12 in total

1.  Interleukin-6, interleukin-6 receptor gene variant, small-vessel disease and incident dementia.

Authors:  K Miwa; S Okazaki; M Sakaguchi; H Mochizuki; K Kitagawa
Journal:  Eur J Neurol       Date:  2016-01-03       Impact factor: 6.089

2.  Circulating Vascular Growth Factors and Magnetic Resonance Imaging Markers of Small Vessel Disease and Atrophy in Middle-Aged Adults.

Authors:  Mekala R Raman; Jayandra J Himali; Sarah C Conner; Charles DeCarli; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri; Pauline Maillard; Claudia L Satizabal
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

3.  VEGF-A inhibits agonist-mediated Ca2+ responses and activation of IKCa channels in mouse resistance artery endothelial cells.

Authors:  Xi Ye; Taylor Beckett; Pooneh Bagher; Christopher J Garland; Kim A Dora
Journal:  J Physiol       Date:  2018-07-02       Impact factor: 5.182

4.  Circulating growth factors and cardiac remodeling in the community: The Framingham Heart Study.

Authors:  Cecilia Castro-Diehl; Rebecca J Song; Douglas B Sawyer; Kai C Wollert; Gary F Mitchell; Susan Cheng; Ramachandran S Vasan; Vanessa Xanthakis
Journal:  Int J Cardiol       Date:  2021-01-07       Impact factor: 4.164

5.  Trajectories of Blood Pressure in Midlife Women: Does Menopause Matter?

Authors:  Saad Samargandy; Karen A Matthews; Maria M Brooks; Emma Barinas-Mitchell; Jared W Magnani; Rebecca C Thurston; Samar R El Khoudary
Journal:  Circ Res       Date:  2022-01-06       Impact factor: 17.367

6.  Anti-Müllerian hormone and its relationships with subclinical cardiovascular disease and renal disease in a longitudinal cohort study of women with type 1 diabetes.

Authors:  Catherine Kim; Yuanyuan Pan; Barbara H Braffett; Valerie L Arends; Michael W Steffes; Hunter Wessells; Aruna V Sarma
Journal:  Womens Midlife Health       Date:  2017-08-18

7.  Cell seeding accelerates the vascularization of tissue engineering constructs in hypertensive mice.

Authors:  Maximilian E H Wagner; Andreas Kampmann; Kathrin Schumann-Moor; Nils-Claudius Gellrich; Frank Tavassol; Friederike Schmeltekop; Martin Rücker; Martin Lanzer; Thomas Gander; Harald Essig; Paul Schumann
Journal:  Hypertens Res       Date:  2020-08-11       Impact factor: 3.872

8.  Vascular Endothelial Growth Factor and Ischemic Heart Disease Risk: A Mendelian Randomization Study.

Authors:  Shiu Lun Au Yeung; Hugh Simon Hung San Lam; C Mary Schooling
Journal:  J Am Heart Assoc       Date:  2017-08-01       Impact factor: 5.501

9.  Follicle-Stimulating Hormone, Its Association with Cardiometabolic Risk Factors, and 10-Year Risk of Cardiovascular Disease in Postmenopausal Women.

Authors:  Ningjian Wang; Hongfang Shao; Yi Chen; Fangzhen Xia; Chen Chi; Qin Li; Bing Han; Yincheng Teng; Yingli Lu
Journal:  J Am Heart Assoc       Date:  2017-08-30       Impact factor: 5.501

10.  Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus.

Authors:  Xiaomeng Sun; Heng Zhang; Jia Liu; Guang Wang
Journal:  J Int Med Res       Date:  2019-09-23       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.